HCW Biologics (HCWB) said Tuesday its board has approved a 1-for-40 reverse split of its common stock, effective April 11, to regain compliance with Nasdaq's $1 minimum bid price requirement.
The move will reduce the company's total number of issued and outstanding common shares to about 1.1 million from 44.9 million.
Shares will start trading on a split-adjusted basis also on April 11.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。